US2008125357A1PendingUtilityA1

Compositions comprising a ligand of chemerinR

55
Assignee: EUROSCREEN SAPriority: Jul 9, 2001Filed: Mar 13, 2006Published: May 29, 2008
Est. expiryJul 9, 2021(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/10A61P 9/12A61P 9/00A61P 37/08A61P 9/04A61P 7/00A61P 37/04A61P 3/10A61P 9/02A61P 25/06A61P 25/18A61P 25/02A61P 25/28A61P 3/04A61P 25/14A61P 25/24A61P 35/00A61P 25/16A61P 25/22A61P 19/10A61P 17/02A61P 13/08C07K 16/28A61P 1/04G01N 33/74C07K 16/18C07K 14/4702A61P 13/00A61P 19/08C07K 2317/34A61K 38/00A61P 21/00G01N 2500/02C07K 14/575C07K 14/47
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Claims

exact text as granted — not AI-modified
1 . A polypeptide comprising an amino acid sequence of SEQ ID No. 73 (the 157 aa truncated sequence). 
     
     
         2 . A composition comprising the polypeptide of  claim 1 . 
     
     
         3 . A therapeutic composition comprising the polypeptide of  claim 1 . 
     
     
         4 . A polypeptide comprising an amino acid sequence of SEQ ID No. 12 (the 143 aa truncated sequence, Prochemerin). 
     
     
         5 . A composition comprising the polypeptide of  claim 4 . 
     
     
         6 . A therapeutic composition comprising the polypeptide of  claim 4 . 
     
     
         7 . A polypeptide comprising an amino acid sequence of SEQ ID No. 14 (the 137 aa truncated sequence, Chemerin). 
     
     
         8 . A composition comprising the polypeptide of  claim 7 . 
     
     
         9 . A therapeutic composition comprising the polypeptide of  claim 7 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.